A small drugmaker is trying to bring a new quit-smoking and quit-vaping medicine to market, helped by regulators and a big unmet need among people who want to stop. The big question is whether approval, funding, and real-world demand arrive fast enough to beat entrenched alternatives and turn the idea into a viable product launch.Read more
Achieve Life Sciences is trying to bring a new medicine for quitting smoking—and potentially vaping—to market, but the path runs through tough approval, launch, and insurance coverage hurdles that could slow real-world uptake. The upside rests on whether it can prove a lean, digital-first launch model and reliable manufacturing while staying funded long enough to reach broad prescribing.Read more
Achieve Life Sciences is nearing a make-or-break moment as its quit-smoking pill heads toward an FDA decision, which could turn it from a research-stage company into one that can finally sell a product. A faster path for a vaping-focused version and a data-driven launch plan could widen the opportunity, but delays, funding needs, or slow doctor and insurer uptake could derail the story.Read more
No trending discussion available.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
